Our article “Mitigation of supply chain challenges in cell therapy manufacturing: perspectives from the cord blood alliance” has been published in Stem Cells Translational Medicine.

This article explores the root causes and impacts of three significant supply chain issues affecting cord blood banking and the broader cell therapy field. It discusses the shortage of Hespan, the discontinuation of medical device marking for the Sepax system, and new European regulations on plasticizers in cord blood collection bags.

The authors present systematic mitigation strategies implemented by cord blood stakeholders to address these challenges, emphasizing the importance of unified efforts to negotiate resolutions with providers and regulators.

read the full article : Mitigation of supply chain challenges in cell therapy manufacturing: perspectives from the cord blood alliance | Stem Cells Translational Medicine | Oxford Academic (oup.com)